Skip to main content

Table 1 Baseline demographic characteristics and clinical outcomes for each biomaker

From: Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Parameter (no.of patients, %)

EGFR mutation

pTyr1068

pTyr1173

  

+

-

p

+

-

p

+

-

p

Total case

92(44.9)

113(55.1)

-

164(80.0)

41(20.0)

-

95(57.6)

70(42.4)

-

Age

<75

85(45.9)

100(54.1)

0.479

148(80.0)

37(20.0)

0.598

86(58.5)

61(41.5)

0.615

 

≥75

7(35.0)

13(65.0)

 

16(80.0)

4(20.0)

 

9(50.0)

9(50.0)

 

Gender

Male

40(40.4)

59(59.6)

0.135

77(77.8)

22(22.2)

0.276

48(57.8)

35(42.2)

0.536

 

Female

52(49.1)

54(50.9)

 

87(82.1)

19(17.9)

 

47(57.3)

35(42.7)

 

Somking history

Never*

59(50.9)

57(49.1)

0.024

94(81.0)

22(19.0)

0.394

49(51.6)

46(48.4)

0.102

 

Ever

26(35.1)

48(64.9)

 

58(78.4)

16(21.6)

 

38(63.3)

22(36.7)

 
 

Unknown

7(46.7)

8(53.3)

 

12(80)

3(20)

 

8(80)

2(20)

 

Histology

ADC

76(45.0)

93(55.0)

0.541

134(79.3)

35(20.7)

0.414

75(55.1)

61(44.9)

0.152

 

Non-ADC

16(45.7)

19(54.3)

 

29(82.9)

6(17.1)

 

19(67.9)

9(32.1)

 
 

Unknown

0

1(100)

 

1(100)

0

 

1(100)

0

 

Disease stage

III

20(57.1)

15(42.9)

0.078

26(74.3)

9(25.7)

0.249

18(60)

12(40)

0.841

 

IV

71(42.3)

97(57.7)

 

136(81.0)

32(19.0)

 

77(57.5)

57(42.5)

 
 

Unknown

1(50)

1(50)

 

2(100)

0

 

0

2(100)

 

TKIs theraphy

Total

89(45.9)

105(54.1)

-

154(79.4)

40(20.6)

-

90(57.7)

66(42.3)

-

Line

First

22(27.4)

32(30.5)

0.623

42(27.3)

12(3.00)

0.843

48(57.8)

35(42.2)

0.365

 

Second

67(72.6)

73(69.5)

 

112(72.7)

28(70.0)

 

47(57.3)

35(42.7)

 

Best response

CR

0(0)

0(0)

<0.001

0(0)

0(0)

<0.001

0(0)

0(0)

0.028

 

PR

43(50.0)

17(17.0)

 

58(39.5)

2(5.1)

 

25(27.8)

25(37.9)

 
 

SD

29(33.7)

42(42.0)

 

57(38.8)

14(35.9)

 

33(36.7)

30(45.5)

 
 

PD

14(15.7)

41(38.3)

 

32(20.8)

23(56.1)

 

32(35.6)

11(16.7)

 

ORR

CR + PR

43(50.0)

17(17.0)

<0.001

58(39.5)

2(5.1)

<0.001

25(27.8)

25(37.9)

0.123

DCR

CR + PR + SD

72(83.7)

59(59.0)

<0.001

115(78.2)

16(41.0)

<0.001

48(57.8)

35(42.2)

0.007

 

PD

14(16.3)

41(41)

 

112(72.7)

28(70.0)

 

47(57.3)

35(42.7)

 

PFS (months)

Median

8.8

2.1

0.024

7

1.2

<0.001

4.8

7.2

0.016

 

95%CI

6.11-11.42

0.89-3.24

 

5.14-8.86

0.96-1.51

 

2.37-7.23

3.69-11.85

 
  1. Abbreviations: EGFR, epidermal growth factor receptor; pTyr, phophorylated tyrosine; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; *Never-smoker refers to patients had never smoked in their lifetime.